


IN THE CLAIMS

Claims 1-34 (**canceled**)

35. **(currently amended)** A polyphosphoester polymer having a block structure, comprising: a monomer unit comprising a polylactide structure; a -P(R)(O)- group where R is equal to -H, -R1 or -O-R1; wherein R1 represents an alkyl, cycloalkyl, aryl, or heteroaryl group; and a chemical moiety bonded through two -C(O)- radicals at its termini; and wherein said monomer unit is represented by formula (I);



wherein L1 is the polylactide structure; L2 is the chemical moiety bonded through two -C(O)- radicals at its termini; and n and w independently of each other represent an integer equal to at least one.

36. **(original)** The polyphosphoester polymer of claim 35, wherein R is -O-R1.
37. **(original)** The polyphosphoester polymer of claim 36, wherein R1 is an ethyl group.
38. **(original)** The polyphosphoester polymer of claim 35, wherein said chemical moiety is -C(O)C₆H₄C(O)-.
39. **(original)** The polyphosphoester polymer of claim 35, wherein said monomer comprises both aromatic and non-aromatic moieties.
40. **(original)** The polyphosphoester polymer of claim 39, wherein the ratio of non-aromatic moieties to aromatic moieties is from about 2:1 to about 8:1.
41. **(original)** The polyphosphoester polymer of claim 40 wherein said ratio of non-aromatic to aromatic moieties in the polyester is about 4:1.

42. (original) The polyphosphoester polymer of claim 39, wherein the ratio of non-aromatic to aromatic moieties in said monomer unit is about 4:1; R is -OC₂H₅; and said chemical moiety is -C(O)C₆H₄C(O)-.
43. (original) The polyphosphoester polymer of claim 39, wherein the number of non aromatic carbons in said monomeric units is greater than the number of aromatic ring carbons in said monomeric units.
44. (original) The polyphosphoester polymer of claim 39, wherein said polyphosphoester polymer is biodegradable.
45. (original) The polyphosphoester polymer of claim 39, wherein said polyphosphoester polymer is biocompatible.
46. (original) A composition comprising said polyphosphoester polymer of claim 45 and one or more biologically active agents.
47. (original) The composition of claim 46, wherein said composition is formulated in a pharmaceutically accepted carrier.
48. (currently amended) A method for treating or preventing ~~a disease or condition~~ cancer, comprising administering to a patient a therapeutically effective amount of any one of the compositions of claim 46.